ArticleCells2022
Hormone-Dependent Cancers: Molecular Mechanisms and Therapeutical Implications.
Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A systematic review and meta-analysis of pregnancy-associated breast cancer incidence rate.BMC cancer · 2025Pooled it
- Gendered interpretations of the causes of breast cancer: a structured review of migrant studies.BMC women's health · 2025Pooled it
- Study of Estrogen Receptor Alpha Gene Polymorphisms (International journal of molecular sciences · 2026Article
- ROS-Fueled Allies: STAT3, PKM2, and HIF-1α Influencing Energy Metabolism in Hormone-Independent Cancers.International journal of molecular sciences · 2026Article
- Sex and gender-oriented colorectal cancer screening: a consensus study from the AIOM- GISEG working group.Frontiers in oncology · 2026Article
- Future landscapes of women's hormone-sensitive cancers: unraveling global trends, age stratification, and regional inequities (1990-2035).Frontiers in endocrinology · 2026Article
- Sex differences in innate immune cell responses: Impact on cancer immunity and response to therapy.Frontiers in immunology · 2026Review
- Discovery and development of steroidal enzyme inhibitors as anti-cancer drugs: state-of-the-art and future perspectives.Journal of enzyme inhibition and medicinal chemistry · 2025Review
- Hybrid Dihydropyrimidinones Targeting AKT Signaling: Antitumor Activity in Hormone-Dependent 2D and 3D Cancer Models.Pharmaceutics · 2025Article
- Systems biology-driven identification of biomarkers and significant pathways in radiation-induced hormone-sensitive cancers.Discover oncology · 2025Article
- Leveraging Synergy: A Review of the Therapeutic Potential of SN-38 and Immune Checkpoint Blockade in Breast and Prostate Cancer Treatment.Journal of personalized medicine · 2025Review
- Therapeutic Potential of Natural Xanthones Against Prostate Adenocarcinoma: A Comprehensive Review of Research Trends During the Last Ten Years (2014-2024).Pharmaceuticals (Basel, Switzerland) · 2025Review
- Epigenetic Therapies in Endocrine-Related Cancers: Past Insights and Clinical Progress.Cancers · 2025Review
- Article
- Pharmaceutical Pollutants: Ecotoxicological Impacts and the Use of Agro-Industrial Waste for Their Removal from Aquatic Environments.Journal of xenobiotics · 2024Review
- Agonists, Antagonists and Receptors of Somatostatin: Pathophysiological and Therapeutical Implications in Neoplasias.Current issues in molecular biology · 2024Review
- Developing a pragmatic consensus procedure supporting the ICH S1B(R1) weight of evidence carcinogenicity assessment.Frontiers in toxicology · 2024Article
- Current status and frontier tracking of clinical trials on Metformin for cancer treatment.Journal of cancer research and clinical oncology · 2023Review
- MMP3C: an in-silico framework to depict cancer metabolic plasticity using gene expression profiles.Briefings in bioinformatics · 2023Article
- Analysis of Single Nucleotide Polymorphisms (SNPs) rs2234693 and rs9340799 of theIn vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hormone-dependent cancers of the breast and prostate are the most common cancers in women and men, respectively [...].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.